The FDA has appointed George Tidmarsh, a seasoned biotech executive and Stanford professor, as director of the Center for Drug Evaluation and Research (CDER), a key leadership role during a period of heightened scrutiny and evolving regulatory challenges. Tidmarsh brings extensive experience in oncology and pediatrics, having led several drug development programs. His appointment follows ongoing pressures on the FDA related to controversial drug approvals and safety concerns, including the Sarepta gene therapy controversy and broad agency reforms under Commissioner Marty Makary.